PFE Dec 2024 24.000 call
| Previous close | 5.75 |
| Open | 5.75 |
| Bid | 4.65 |
| Ask | 5.60 |
| Strike | 24.00 |
| Expiry date | 2024-12-20 |
| Day's range | 5.75 - 5.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 297 |
ReutersPfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.
ZacksAbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Investor's Business DailyPfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?
